Role of Type2Inflammation Across Different Chronic Diseases
Type 2 Inflammation
Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type2inflammation contributes to key symptoms of inflammatory diseases across organs
Role of Type2Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
Dr. Robert Bissonnette explains the role of type2inflammation in skin barrier dysfunction and how regulation of type2inflammation can normalize the skin barrier and potentially modify the disease with early intervention.
Type2Inflammation in AD Manifestations in Skin and Body
Type 2 Inflammation
Dr. Ramien discusses the role of type2inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.
ATS 2024 | Type2Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type2inflammation in asthma and COPD.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.